Altamira Therapeutics Ltd

CYTOF
$0.06 (+ $0.00 + 0.00%)
Last updated: Previous Close (2026-06-26)
CYTOF Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealth Care
IndustryBiotechnology
ISINBMG0360L1349
Market Price0.06
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPSN/A
Market Cap$354,359
Book Value0.71
Price to Book0.087
BetaN/A
52w High0.15
52w Low0.05
Next Earnings DateN/A

Altamira Therapeutics Ltd trades under ticker CYTOF on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Health Care exposure. Identifiers: ISIN BMG0360L1349. Also searched as Altamira Therapeutics.

Related researchCYTOF stock priceCYTOF share priceAltamira Therapeutics stockAltamira Therapeutics share price
About the Company
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II clinical trial for the intranasal treatment of vertigo. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
Price History